Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma

Satoshi Kobayashi, Takeshi Terashima, Satoshi Shiba, Yukio Yoshida, Ikuhiro Yamada, Shouta Iwadou, Shigeru Horiguchi, Hideaki Takahashi, Eiichiro Suzuki, Michihisa Moriguchi, Kunihiro Tsuji, Taiga Otsuka, Akinori Asagi, Yasushi Kojima, Ryoji Takada, Chigusa Morizane, Nobumasa Mizuno, Masafumi Ikeda, Makoto Ueno, Junji Furuse

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We conducted a multicenter retrospective analysis to evaluate the efficacy of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma. We enrolled 36 patients with pathologically proven, unresectable combined hepatocellular and cholangiocarcinoma treated with systemic chemotherapy. The log-rank test determined the significance of each prognostic factor. Elevated alpha-fetoprotein, carcinoembryonic antigen and carbohydrate antigen 19-9 levels were observed in 58.3%, 16.7% and 38.9% of patients, respectively. First-line chemotherapy included platinum-containing regimens consisting of gemcitabine/cisplatin (n = 12) and fluorouracil/cisplatin (n = 11), sorafenib (n = 5) and others (n = 8). The median overall and progression-free survival times were 8.9 and 2.8 months, respectively, with an overall response rate of 5.6%. Prognostic factors associated with negative outcomes included poor performance status, no prior primary tumor resection, a Child-Pugh class of B, and elevated carcinoembryonic antigen levels with a hazard ratio of 2.25, 2.48, 3.25 and 2.84 by univariate analysis, respectively. The median overall survival times of the gemcitabine/cisplatin, fluorouracil/cisplatin, sorafenib and other groups were 11.9, 10.2, 3.5 and 8.1 months, respectively. Multivariate analysis revealed that the overall survival of patients within the sorafenib monotherapy group was poor compared with platinum-containing regimens (HR: 15.83 [95% CI: 2.25-111.43], P =.006). All 7 patients in the sorafenib group had progressive disease, including 2 patients with second-line therapy. In conclusion, the platinum-containing regimens such as gemcitabine/cisplatin were associated with more favorable outcomes than sorafenib monotherapy for unresectable combined hepatocellular and cholangiocarcinoma.

Original languageEnglish
Pages (from-to)2549-2557
Number of pages9
JournalCancer Science
Volume109
Issue number8
DOIs
Publication statusPublished - Aug 1 2018

Fingerprint

gemcitabine
Cholangiocarcinoma
Cisplatin
Drug Therapy
Platinum
Carcinoembryonic Antigen
Fluorouracil
Survival
alpha-Fetoproteins
Disease-Free Survival
Multivariate Analysis
Carbohydrates
sorafenib
Antigens
Neoplasms

Keywords

  • Cisplatin
  • drug therapy
  • gemcitabine
  • prognosis
  • sorafenib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kobayashi, S., Terashima, T., Shiba, S., Yoshida, Y., Yamada, I., Iwadou, S., ... Furuse, J. (2018). Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma. Cancer Science, 109(8), 2549-2557. https://doi.org/10.1111/cas.13656

Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma. / Kobayashi, Satoshi; Terashima, Takeshi; Shiba, Satoshi; Yoshida, Yukio; Yamada, Ikuhiro; Iwadou, Shouta; Horiguchi, Shigeru; Takahashi, Hideaki; Suzuki, Eiichiro; Moriguchi, Michihisa; Tsuji, Kunihiro; Otsuka, Taiga; Asagi, Akinori; Kojima, Yasushi; Takada, Ryoji; Morizane, Chigusa; Mizuno, Nobumasa; Ikeda, Masafumi; Ueno, Makoto; Furuse, Junji.

In: Cancer Science, Vol. 109, No. 8, 01.08.2018, p. 2549-2557.

Research output: Contribution to journalArticle

Kobayashi, S, Terashima, T, Shiba, S, Yoshida, Y, Yamada, I, Iwadou, S, Horiguchi, S, Takahashi, H, Suzuki, E, Moriguchi, M, Tsuji, K, Otsuka, T, Asagi, A, Kojima, Y, Takada, R, Morizane, C, Mizuno, N, Ikeda, M, Ueno, M & Furuse, J 2018, 'Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma', Cancer Science, vol. 109, no. 8, pp. 2549-2557. https://doi.org/10.1111/cas.13656
Kobayashi, Satoshi ; Terashima, Takeshi ; Shiba, Satoshi ; Yoshida, Yukio ; Yamada, Ikuhiro ; Iwadou, Shouta ; Horiguchi, Shigeru ; Takahashi, Hideaki ; Suzuki, Eiichiro ; Moriguchi, Michihisa ; Tsuji, Kunihiro ; Otsuka, Taiga ; Asagi, Akinori ; Kojima, Yasushi ; Takada, Ryoji ; Morizane, Chigusa ; Mizuno, Nobumasa ; Ikeda, Masafumi ; Ueno, Makoto ; Furuse, Junji. / Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma. In: Cancer Science. 2018 ; Vol. 109, No. 8. pp. 2549-2557.
@article{b71b2f10da4742eaab2b026d1acf9fdd,
title = "Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma",
abstract = "We conducted a multicenter retrospective analysis to evaluate the efficacy of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma. We enrolled 36 patients with pathologically proven, unresectable combined hepatocellular and cholangiocarcinoma treated with systemic chemotherapy. The log-rank test determined the significance of each prognostic factor. Elevated alpha-fetoprotein, carcinoembryonic antigen and carbohydrate antigen 19-9 levels were observed in 58.3{\%}, 16.7{\%} and 38.9{\%} of patients, respectively. First-line chemotherapy included platinum-containing regimens consisting of gemcitabine/cisplatin (n = 12) and fluorouracil/cisplatin (n = 11), sorafenib (n = 5) and others (n = 8). The median overall and progression-free survival times were 8.9 and 2.8 months, respectively, with an overall response rate of 5.6{\%}. Prognostic factors associated with negative outcomes included poor performance status, no prior primary tumor resection, a Child-Pugh class of B, and elevated carcinoembryonic antigen levels with a hazard ratio of 2.25, 2.48, 3.25 and 2.84 by univariate analysis, respectively. The median overall survival times of the gemcitabine/cisplatin, fluorouracil/cisplatin, sorafenib and other groups were 11.9, 10.2, 3.5 and 8.1 months, respectively. Multivariate analysis revealed that the overall survival of patients within the sorafenib monotherapy group was poor compared with platinum-containing regimens (HR: 15.83 [95{\%} CI: 2.25-111.43], P =.006). All 7 patients in the sorafenib group had progressive disease, including 2 patients with second-line therapy. In conclusion, the platinum-containing regimens such as gemcitabine/cisplatin were associated with more favorable outcomes than sorafenib monotherapy for unresectable combined hepatocellular and cholangiocarcinoma.",
keywords = "Cisplatin, drug therapy, gemcitabine, prognosis, sorafenib",
author = "Satoshi Kobayashi and Takeshi Terashima and Satoshi Shiba and Yukio Yoshida and Ikuhiro Yamada and Shouta Iwadou and Shigeru Horiguchi and Hideaki Takahashi and Eiichiro Suzuki and Michihisa Moriguchi and Kunihiro Tsuji and Taiga Otsuka and Akinori Asagi and Yasushi Kojima and Ryoji Takada and Chigusa Morizane and Nobumasa Mizuno and Masafumi Ikeda and Makoto Ueno and Junji Furuse",
year = "2018",
month = "8",
day = "1",
doi = "10.1111/cas.13656",
language = "English",
volume = "109",
pages = "2549--2557",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma

AU - Kobayashi, Satoshi

AU - Terashima, Takeshi

AU - Shiba, Satoshi

AU - Yoshida, Yukio

AU - Yamada, Ikuhiro

AU - Iwadou, Shouta

AU - Horiguchi, Shigeru

AU - Takahashi, Hideaki

AU - Suzuki, Eiichiro

AU - Moriguchi, Michihisa

AU - Tsuji, Kunihiro

AU - Otsuka, Taiga

AU - Asagi, Akinori

AU - Kojima, Yasushi

AU - Takada, Ryoji

AU - Morizane, Chigusa

AU - Mizuno, Nobumasa

AU - Ikeda, Masafumi

AU - Ueno, Makoto

AU - Furuse, Junji

PY - 2018/8/1

Y1 - 2018/8/1

N2 - We conducted a multicenter retrospective analysis to evaluate the efficacy of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma. We enrolled 36 patients with pathologically proven, unresectable combined hepatocellular and cholangiocarcinoma treated with systemic chemotherapy. The log-rank test determined the significance of each prognostic factor. Elevated alpha-fetoprotein, carcinoembryonic antigen and carbohydrate antigen 19-9 levels were observed in 58.3%, 16.7% and 38.9% of patients, respectively. First-line chemotherapy included platinum-containing regimens consisting of gemcitabine/cisplatin (n = 12) and fluorouracil/cisplatin (n = 11), sorafenib (n = 5) and others (n = 8). The median overall and progression-free survival times were 8.9 and 2.8 months, respectively, with an overall response rate of 5.6%. Prognostic factors associated with negative outcomes included poor performance status, no prior primary tumor resection, a Child-Pugh class of B, and elevated carcinoembryonic antigen levels with a hazard ratio of 2.25, 2.48, 3.25 and 2.84 by univariate analysis, respectively. The median overall survival times of the gemcitabine/cisplatin, fluorouracil/cisplatin, sorafenib and other groups were 11.9, 10.2, 3.5 and 8.1 months, respectively. Multivariate analysis revealed that the overall survival of patients within the sorafenib monotherapy group was poor compared with platinum-containing regimens (HR: 15.83 [95% CI: 2.25-111.43], P =.006). All 7 patients in the sorafenib group had progressive disease, including 2 patients with second-line therapy. In conclusion, the platinum-containing regimens such as gemcitabine/cisplatin were associated with more favorable outcomes than sorafenib monotherapy for unresectable combined hepatocellular and cholangiocarcinoma.

AB - We conducted a multicenter retrospective analysis to evaluate the efficacy of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma. We enrolled 36 patients with pathologically proven, unresectable combined hepatocellular and cholangiocarcinoma treated with systemic chemotherapy. The log-rank test determined the significance of each prognostic factor. Elevated alpha-fetoprotein, carcinoembryonic antigen and carbohydrate antigen 19-9 levels were observed in 58.3%, 16.7% and 38.9% of patients, respectively. First-line chemotherapy included platinum-containing regimens consisting of gemcitabine/cisplatin (n = 12) and fluorouracil/cisplatin (n = 11), sorafenib (n = 5) and others (n = 8). The median overall and progression-free survival times were 8.9 and 2.8 months, respectively, with an overall response rate of 5.6%. Prognostic factors associated with negative outcomes included poor performance status, no prior primary tumor resection, a Child-Pugh class of B, and elevated carcinoembryonic antigen levels with a hazard ratio of 2.25, 2.48, 3.25 and 2.84 by univariate analysis, respectively. The median overall survival times of the gemcitabine/cisplatin, fluorouracil/cisplatin, sorafenib and other groups were 11.9, 10.2, 3.5 and 8.1 months, respectively. Multivariate analysis revealed that the overall survival of patients within the sorafenib monotherapy group was poor compared with platinum-containing regimens (HR: 15.83 [95% CI: 2.25-111.43], P =.006). All 7 patients in the sorafenib group had progressive disease, including 2 patients with second-line therapy. In conclusion, the platinum-containing regimens such as gemcitabine/cisplatin were associated with more favorable outcomes than sorafenib monotherapy for unresectable combined hepatocellular and cholangiocarcinoma.

KW - Cisplatin

KW - drug therapy

KW - gemcitabine

KW - prognosis

KW - sorafenib

UR - http://www.scopus.com/inward/record.url?scp=85052502984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052502984&partnerID=8YFLogxK

U2 - 10.1111/cas.13656

DO - 10.1111/cas.13656

M3 - Article

C2 - 29856900

AN - SCOPUS:85052502984

VL - 109

SP - 2549

EP - 2557

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 8

ER -